What is the appropriate lacosamide dosing regimen for a child with partial‑onset seizures, including starting dose, titration schedule, maximum dose, and adjustments for renal or hepatic impairment?

Lacosamide Dosing for Pediatric Partial-Onset Seizures

For children with partial-onset seizures, initiate lacosamide at 2 mg/kg/day (divided twice daily), uptitrate by 2 mg/kg/day weekly to a target maintenance dose of 8–12 mg/kg/day (maximum 600 mg/day), with no specific renal or hepatic dose adjustments established in pediatric populations. 1

Starting Dose and Titration Schedule

• Initial dose: Begin at 2 mg/kg/day, administered as 1 mg/kg twice daily (BID). 1
• Titration rate: Increase by 2 mg/kg/day per week during the uptitration phase. 1
• Titration duration: The flexible titration period typically spans 6 weeks to reach the target maintenance dose. 1, 2
• Target maintenance dose: Aim for 8–12 mg/kg/day (not to exceed 600 mg/day absolute maximum). 1, 2

Age-Specific Considerations

• This dosing regimen has been validated in children from 6 months to ≤17 years of age with focal seizures. 1
• Even infants and young children under 4 years can be treated with this approach, with studies showing efficacy at final doses ranging from 7–15.5 mg/kg/day. 3
• In critically ill children, including young infants, lacosamide has demonstrated acceptable safety and efficacy when used early in the treatment sequence. 4

Maximum Dose

• Weight-based maximum: 12 mg/kg/day. 1, 2
• Absolute maximum: 600 mg/day, regardless of weight. 1, 2
• In clinical practice, maintenance dosages have ranged from 2.4 to 19.4 mg/kg/day in refractory cases, though doses above 12 mg/kg/day are not formally recommended. 5

Adjustments for Renal Impairment

• No established pediatric-specific guidelines exist for renal dose adjustment. 6
• In a case report of a 2-year-old with end-stage kidney disease on peritoneal dialysis, lacosamide was carefully titrated with close monitoring of blood levels, which increased linearly to the optimal therapeutic range. 6
• Caution is warranted: Lacosamide is renally excreted, and removal via peritoneal dialysis is less efficient than hemodialysis, necessitating vigilant monitoring to avoid drug accumulation. 6
• Practical approach: Start at the lower end of the dosing range (2 mg/kg/day) and titrate slowly with frequent therapeutic drug monitoring in children with significant renal impairment. 6

Adjustments for Hepatic Impairment

• No pediatric-specific data are available for hepatic dose adjustments.
• In the absence of evidence, consider starting at the lower end of the dosing range and titrating cautiously with clinical and laboratory monitoring.

Efficacy and Safety Profile

• Efficacy in focal seizures: In an open-label trial of children aged 6 months to ≤17 years, 51.1% completed the trial at the maximum cohort-defined dose, and lacosamide was particularly effective for partial-onset seizures (62.5% response rate in localization-related epilepsies). 1, 5
• Responder rates: After 3 months of adjunctive therapy in infants and young children, 42% were responders (>50% seizure reduction), with 17% achieving seizure freedom. 3
• Status epilepticus: In critically ill children with acute repetitive seizures or convulsive status epilepticus, early use of intravenous lacosamide (loading dose ~10 mg/kg) showed high efficacy, with seizure cessation rates of 100% when used as first-line and 85.7% as second-line in previously healthy children. 7, 4

Common Adverse Events

• Most frequent: Vomiting (21.3%), diarrhea (14.9%), somnolence (12.8%), irritability, dizziness, and pyrexia (10.6% each). 1
• Discontinuation rate: 42.6% discontinued due to treatment-emergent adverse events (TEAEs), most commonly vomiting (8.5%), gait disturbance, dizziness, and somnolence (6.4% each). 1
• Cardiac effects: Bradycardia was observed in 23.9% of critically ill children receiving intravenous lacosamide, warranting cardiac monitoring. 4
• Serious adverse events: Status epilepticus occurred in 6.4% of patients, though this may reflect underlying disease severity rather than drug effect. 1

Key Clinical Pitfalls and Caveats

• Fixed-titration protocols: In trials using fixed titration schedules, patients who did not achieve the maximum cohort-defined dose were discontinued, which may have inflated discontinuation rates. 1 In real-world practice, slower or more flexible titration may improve tolerability.
• Loss of efficacy over time: In infants and young children, 50% of initial responders experienced loss of efficacy after 12 months, with only 22% maintaining improvement long-term. 3 This highlights the need for ongoing monitoring and potential dose adjustments or medication changes.
• Drug interactions: Lacosamide has minimal drug interactions, making it advantageous in polytherapy regimens. 6 Concomitant use of valproic acid, levetiracetam, oxcarbazepine, lamotrigine, and perampanel does not significantly alter lacosamide pharmacokinetics. 8
• Pharmacogenomics: Genetic polymorphisms in CYP2C19, ABCB1, and ABCC2 do not have clinically significant effects on lacosamide pharmacokinetics in children. 8
• Elevated uric acid: In children with uric acid levels >400 μmol/L, consider reducing the dose by approximately 50% compared to those with normal uric acid levels (100 μmol/L), as elevated uric acid significantly affects lacosamide clearance. 8

Dosing for Missed or Delayed Doses

• Individualized remedial doses: Depending on the delayed time, administer 0.5- to 1.5-fold of the regular dose to maintain therapeutic levels. 8
• Body surface area (BSA)-based dosing: BSA is a significant covariate for lacosamide clearance, and BSA-based dosing regimens may optimize individualization. 8

Context Within Broader Pediatric Epilepsy Guidelines

• Lacosamide is not mentioned in older American Academy of Neurology/American Epilepsy Society guidelines (2004) for refractory partial epilepsy in children, as it was not yet available. 9
• Established adjunctive therapies for pediatric refractory partial seizures include gabapentin (23–35 mg/kg/day), lamotrigine (1–5 mg/kg/day with enzyme inducers; 1–3 mg/kg/day with valproate), oxcarbazepine (30–46 mg/kg/day), and topiramate (125–400 mg/day). 9
• Neonatal seizures: Lacosamide is not recommended as first- or second-line therapy for neonatal seizures; phenobarbital remains first-line, with phenytoin or levetiracetam as second-line options. 10